Progress in Neurotherapeutics and Neuropsychopharmacology: v. 2

Progress in Neurotherapeutics and Neuropsychopharmacology: v. 2

  • £22.89
  • Save £104

Edited by Jeffrey L. Cummings
Cambridge University Press
Edition: 2007 ed., 4/12/2007
EAN 9780521862547, ISBN10: 052186254X

Hardcover, 284 pages, 24.4 x 17 x 1.7 cm
Language: English

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

1. Progress in Neurotherapeutics and Neuropsychopharmacology 2007 Jeffrey L. Cummings
2. A randomized trial comparing unilateral pallidotomy with bilateral subthalamic nucleus stimulation in PD
perspectives for future implication in clinical practice Rianne A. J. Esselink, Rob M. A. de Bie, Rob J. de Haan, P. Richard Schuurman, Pepijn van den Munckhof and Johannes D. Speelman
3. The phase II futility clinical trial design Bernard Ravina and Yuko Palesch
4. Clinical trials in dementia Encarnita Raya-Ampil and Jeffrey L. Cummings
5. Comparative neuropsychological effects of Lamotrigine and Topiramate in healthy volunteers Kimford J. Meador
6. Pilot clinical trial of NT-3 in CMT1A patients Zerife Sahenk
7. New directions in pediatric neuro-oncology practice
impact of the Children's Cancer Group Study 9933, a phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma Tobey J. MacDonald
8. Chemoradiotherapy for primary CNS lymphoma Antonio M. P. Omuro, Joachim Yahalom and Lauren E. Abrey
9. A double-blind, randomized clinical trial to assess the augmentation with Nimodipine of antidepressant therapy in the treatment of 'vascular depression' F. E. Taragano, P. M. Bagnati and R. F. Allegri
10. Repetitive transcranial magnetic stimulation
a novel, noninvasive add-on treatment for medication-resistant depression Tung-Ping Su and Chih-Chia Huang
11. The NIMH MATRICS initiative
development of a consensus cognitive battery Robert S. Kern, Michael F. Green and Stephen R. Marder
12. Review of a randomized controlled trial of adjunctive Bupropion in the treatment of SSRI-induced sexual dysfunction Anna Lembke and Charles DeBattista
13. Trial-based advances in the treatment of bipolar depression David E. Kemp, Keming Gao, David J. Muzine, Prashant Gajwani and Joseph R. Calabrese
14. Symptomatic remission in patients with bipolar mania
results from a double-blind, placebo-controlled trial of Risperidone monotherapy Srihari Gopal, John L. Beyer, David C. Steffens and Michelle L. Kramer
15. Olanzapine as maintenance therapy in patients with bipolar I disorder Mauricio Tohen and Daniel Yen Lin
16. Can quality of life be improved in schizophrenia? Results from a pragmatic, randomized controlled trial comparing Olanzapine with first generation antipsychotics Mauricio Silva de Lima, Alan Breier and Jair de Jesus Mari
17. Combined behavioral and pharmacological treatment of opioid-dependent adolescents
a randomized, controlled trial Lisa A. Marsch.